Gilead Sciences has entered into a definitive agreement to acquire Tubulis GmbH, a German biotechnology company developing next-generation antibody-drug conjugates (ADCs). The transaction includes an upfront cash payment of USD 3.15 billion and potential additional milestone payments of up to USD 1.85 billion, for a total deal value of up to USD 5 billion. The acquisition is expected to close in Q2 2026 and significantly expands Gilead's oncology pipeline and ADC capabilities.

Tubulis's lead asset, TUB-040, is a NaPi2b-targeting ADC conjugated to a topoisomerase I inhibitor (Topo Ii) payload, currently in Ib/II stage development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). The acquisition also provides Gilead with TUB-030, a 5T4-targeting ADC that has shown promising early clinical data.

PharmCube's NextBiopharm® database shows that this is the fifth-largest M&A transaction involving an ADC company. Click here to request a free trial for NextBiopharm®.